Immunic, Inc. (IMUX), a biotechnology company, Wednesday reported positive data from its phase 2 CALLIPER study of vidofludimus calcium in patients with progressive multiple sclerosis (PMS).
In the study patients were randomized to receive either vidofludimus calcium or placebo for up to 120 weeks. Vidofludimus calcium reduced the relative risk of 24-week confirmed disability worsening (24wCDW) events by 20% compared to placebo. The reduction was 30% in the primary progressive multiple sclerosis (PPMS) study population.
A consistent reduction of disability worsening was observed in the different subpopulations with or without inflammatory lesions. Vidofludimus calcium reduced the relative risk of 24wCDW events in patients without gadolinium-enhancing lesions at baseline by 29% compared to placebo.
The company's phase 3 study of vidofludimus calcium in relapsing multiple sclerosis is ongoing and expected to be completed in 2026.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.